References
- Green L. An overview and update of psoriasis. Nurs Stand. 2011;25:47–55
- Gudjonsson J, Elder J. Psoriasis: epidemiology. Clin Dermatol. 2007;25:535–46
- Liu Y, Krueger J, Bowcock A. Psoriasis: genetic associations and immune system changes. Genes Immun. 2007;8:1–12
- Ryan S. Psoriasis: characteristics, psychosocial effects and treatment options. Br J Nurs. 2010;19:820, 822–5
- Farley E, Menter A. Psoriasis: comorbidities and associations. G Ital Dermatol Veneorol. 2011;146:9–15
- Kim N, Thrash B, Menter A. Comorbidities in psoriasis patients. Semin Cutan Med Surg. 2010;29:10–15
- Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007;157:68–73
- Love TJ, Qureshi AA, Karlson EW, et al. Prevalence of metabolic syndrome in psoriasis. Results from the national health and nutrition examination survey, 2003–2006. Arch Dermatol. 2011;147:419–24
- Alsufyani M, Golant A, Lebwohl M. Psoriasis and the metabolic syndrome. Dermatol Ther. 2010;23:137–43
- Chen YJ, Wu CY, Shen JL, et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome. Arch Dermatol. 2008;144:1571–5
- Gerdes S, Rostami-Yazdi M, Mrowietz U. Adipokines and psoriasis. Exp Dermatol. 2011;20:81–7
- Herron MD, Hinckley M, Hoffman MS, et al. The impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol. 2005;141:1527–34
- Naldi L, Chatenoud L, Linder D, et al. Cigarette smoking, body mass index, and stressfull life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125:61–7
- Bik W. To assess the relationship secretion of adipokines and insulin resistance and association of selected polymorphisms of adiponectin and resistin genes in obesity. Post Nauk Med. 2009;12:912–80
- Skrzeczyńska-Moncznik J, Wawro K, Stefańska A, et al. Potential role of chemerin in recruitment of plasmacytoid dendritic cells to diseased skin. Biochem Biophys Res Commun. 2009;380:323–27
- Kirby B, Richards H, Karvonen J, et al. Alcohol consumption and psychological distress in patients with psoriasis. Br J Dermatol. 2008;158:138–40
- Coimbra S, Oliveira H, Reis F, et al. Circulating adipokine levels in Portuguese patients with psoriasis vulgaris according to body mass index, severity and therapy. J Eur Acad Dermatol Venereol. 2010;24:1386–94
- Conde J, Scotece M, Gómez R, et al. At the crossroad between immunity and metabolism: focus on leptin. Expert Rev Clin Immunol. 2010;6:801–8
- Shibata S, Tada Y, Hau C, et al. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br J Dermatol. 2011;164:667–70
- Cerman AA, Bozkurt S, Sav A, et al. Serum leptin levels, skin leptin and leptin receptor expression in psoriasis. Br J Dermatol. 2008;159:820–6
- Chandran M, Phillips S, Ciaraldi T, et al. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003;26:2442–50
- Flisiak I, Zaniewski P, Rogalska M, et al. Effect of psoriasis activity on VEGF and its soluble receptors concentrations in serum and plaque scales. Cytokine. 2010;52:225–9
- Fredriksson T, Pettersen U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica. 1978;157:238–44
- Kaur S, Zilmer K, Leping V, Zilmer M. The levels of adiponectin and leptin and their relation to other markers of cardiovascular risk in patients with psoriasis. J Eur Acad Dermatol Venereol. 2011;25:1328–33
- Takahashi H, Tsuji H, Takahashi I, et al. Plasma adiponectin and leptin levels in Japanese patients with psoriasis. Br J Dermatol. 2008;159:1207–8
- Janusz I, Lewandowski K, Lukamowicz J, et al. Assessment of insulin resistance and adiponectin in patients with psoriasis vulgaris. Adv Dermatol Alergol. 2010;XXVII:451–5
- Johnston A, Arnadottir S, Gudjonsson JE. Obesity in psoriasis: leptin and resistin as mediators of cutaneous inflammation. Br J Dermatol. 2008;159:342–50
- Kaur S, Zilmer K, Kairane C, et al. Clear differences in adiponectin level and glutathione redox status revealed in obese and normal-weight patients with psoriasis. Br J Dermatol. 2008;159:1364–7
- Nakajima H, Nakajima K, Tarutani M, et al. Kinetics of circulating cytokines and adipokines in psoriasis patients. Arch Dermatol Res. 2011;303:451–5
- Gerdes S, Osadtschy S, Rostami-Yazdi M, et al. Leptin, adiponectin, visfatin and retinol-binding protein-4-mediators of comorbidities in patients with psoriasis? Exp Dermatol. 2012;21:43–7
- Ozdemir M, Yüksel M, Gökbel H, et al. Serum leptin, adiponectin, resistin and ghrelin levels in psoriatic patients treated with cyclosporine. J Dermatol. 2012;39:443–8
- Abdel Hay RM, Rashed LA. Association between the leptin gene 2548G/A polymorphism, the plasma leptin and the metabolic syndrome with psoriasis. Exp Dermatol. 2011;20:715–19
- Wang Y, Chen J, Zhao Y, et al. Psoriasis is associated with increased levels of serum leptin. Br J Dermatol. 2008;158:1134–5
- Corbetta S, Angioni R, Cattaneo A, et al. Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines. Eur J Endocrinol. 2006;154:83–6
- Shibata S, Tada Y, Hau C, et al. Adiponectin as an anti-inflammatory factor in the pathogenesis of psoriasis: induction of elevated serum adiponectin levels following therapy. Br J Dermatol. 2011;164:667–70
- Kawashima K, Torii K, Furuhashi T, et al. Phototherapy reduces serum resistin levels in psoriasis patients. Photodermatol Photoimmunol Photomed. 2011;27:152–5